Search This Blog

Tuesday, January 14, 2020

Bill Frist launches CareBridge, new health care tech backed by Google

Former U.S. Sen. Bill Frist will lead a new Nashville health technology company designed to improve care for an increasing number of elderly and disabled Americans who receive medical or support services in their homes.
CareBridge, announced in a news release on Monday, is headquartered in East Nashville and backed by more than $40 million of investments from Google and venture capitalists.
CareBridge was formed in part by the recent purchase of HealthStar, a similarly-focused technology company in Knoxville.
Frist, who will be chairman of the CareBridge board, said in an interview the company will used predictive modeling and data aggregation to modernize care for people who receive long-term support services in their homes.  Frist described the existing administrative systems for this care – a state-by-state hodgepodge of Medicare, Medicaid and insurance companies – as “highly fragmented and dysfunctional.”
CareBridge will also offer round-the-clock support of high-risk patients by deploying tablets into their homes.
“What we bring is an experienced team of people — and a proprietary technology with analytics we believe are the best in class — that are specifically focused on these vulnerable populations,” Frist said.
Long-term support services provide medical care and routine assistance to people with chronic illnesses or physical limitations who need help with daily activities like bathing, dressing, preparing meals and taking medication. Historically, this assistance was provided in nursing homes but in recent years services have shifted towards in-home care designed to allow patients to live as independently as possible. Millions of Americans already depend on this kind of care, and that population is all but guaranteed to grow as the baby boomer generation continues to age.

Anthem and United Healthcare are CareBridge customers

In a news release, CareBridge said it can streamline the administration of long-term support services through “electronic visit verification” and “real-time sharing of clinical information between members, caregivers, health plans and state officials.” The company also said it offers the nation’s first predictive model for determining the amount of services needed by someone who gets care in their home.
“Some of this is in place out there … but nobody else has the whole platform and nobody has it integrated,” said Mike Tudeen, the new CEO of CareBridge, who previously led Nashville-area health care companies PopHealthcare and Inspiris.
“We are excited to do our part to uplift how this is done in our country,” he added.
Tudeen said CareBridge launches with three customers: Anthem and United Healthcare in Tennessee and Horizon Health Care in New Jersey. In the news release announcing the new company, leaders of both Anthem and United praised CareBridge as uniquely prepared to improve long-term support services.
“No other company in the country is developing such a broad array of services for LTSS members,” said United CEO Keith Payet. “By providing such comprehensive services, CareBridge has the opportunity to meaningfully increase the quality of care for LTSS members across the United States.”
CareBridge was launched with a $40 million of investments from multiple sources: Oak HC/FT, a venture capitalist firm focused on health care; GV, the investment arm of Google; and CEOs of several other health care companies, including Nashville-area companies myNexus and Psychiatric Medical Care. Frist and Tudeen declined to reveal how much money had come from individual investors.

Livongo to add data from Dexcom diabetes monitors into its system

Digital health company Livongo struck a deal with Dexcom to integrate the devicemaker’s continuous glucose monitors into Livongo’s system, according to STAT.
Livongo uses data to help people manage chronic conditions. It provides services for diabetes, hypertension, weight management and behavioral health. It works by collecting data from its users and giving tailored health tips based on that data.
For its diabetes patients, Livongo will now be able to use data from Dexcom’s continuous glucose monitors to send personalized health tips. Dexcom’s device reads a patient’s blood glucose level every five minutes, offering 288 data points per patient per day that Livongo can use to offer more relevant advice, STAT reported.
The deal with Dexcom gives Livongo a much larger set of data for its diabetes patients, as it currently only gets blood sugar data a handful of times using its own device.
Livongo won’t supply Dexcom’s monitors to its users, so only people who already use Dexcom’s monitor will be able to participate.
Read the full article here.

Eloxx Pharma down 30% on underwhelming data on lead candidate

Thinly traded micro cap Eloxx Pharmaceuticals (ELOX -29.6%) slumps on 82% higher volume, a modest 527K shares, on the heels of its update on lead drug ELX-02, a eukaryotic ribosomal selective glycoside (ERSG) that, it says, is designed to increase the read-through activity in patients with nonsense mutations and enable the production of sufficient amounts of full-length functional protein to restore activity. It is in development for the potential treatment of cystic fibrosis patients who harbor at least one G542X allele and nephropathic cystinosis (NC), an inherited lysosomal storage disorder caused by the defective transport of cystine out of lysosomes (cystine builds up and crystallizes within lysosomes causing widespread damage).
Investors appear to be reacting to preliminary data from a Phase 2 study in NC evaluating three dose regimens of ELX-02. Reductions in white blood cell (WBC) cystine were observed in the two higher doses in the first cohort (n=3) but none of the reductions reached the therapeutic objective. The lowest dose failed to demonstrate any treatment effect on WBC cystine.
The results were also a bit uneven as measured by serum creatinine (elevations indicate kidney problems) and eGFR (measure of how well the kidneys are working – lower values indicate problems). Two patients showed improvements in the two measures at week 4 of follow-up while one did not.
The company says it is reviewing the data with experts to determine if the protocol needs modification before it initiates the second cohort.

Integra LifeSciences sees Q4 revenue at low end of guidance range

On a preliminary basis, Integra LifeSciences (NASDAQ:IART) sees Q4 revenues at or near the bottom of its previously announced range of $395M – 400M.
Preliminary 2020 guidance: Revenues: $1.55B – 1.57B (+3%); EPS growth: double-digit.
The company plans to implement a share repurchase program authorized to buy back up to $225M of its common stock.
#JPM20

Momenta adds to rally as JPMorgan upgrades

Momenta Pharmaceuticals (NASDAQ:MNTA) is up 5.1% after hours, building on day’s gains of 23.7% after JPMorgan raised its rating to Overweight.
After the company put out its 2020 outlook, analyst Eric Joseph pointed out that results from the phase 1/2 study of M254 in idiopathic thrombocytopenic purpura were compelling, with relative potency compared to a more conventional IVIg approach.
He’s increased his year-end target to $30 from $14, now implying 18% upside.
Sell-side analysts are Bullish overall, while the stock has a Quant Rating of Neutral.

UnitedHealth Q4 2019 Earnings Preview

UnitedHealth (NYSE:UNH) is scheduled to announce Q4 earnings results on Wednesday, January 15th, before market open.
The consensus EPS Estimate is $3.78 (+15.2% Y/Y) and the consensus Revenue Estimate is $61.17B (+4.7% Y/Y).
Over the last 2 years, UNH has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 17 upward revisions and 4 downward. Revenue estimates have seen 3 upward revisions and 10 downward.

Nektar Therapeutics tumbles after FDA panel thumbs down

The vote at today’s joint FDA advisory committee meeting was 27 – 0 against approval of Nektar Therapeutics’ (NASDAQ:NKTR) oxycodegol for chronic low back pain.
Shares down 12% after hours.